Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Goentzel

Pain Medicine Wichita, KS Medical Doctor

NPI 1194959692 CMS profile 99319

1947 N Founders Cir, Wichita, KS 67206

Open in the dashboard

General payments

$98,514

247 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Goentzel of Wichita, KS is reported in the CMS Open Payments database as having received $98,514 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,656 30
2024 General $23,120 43
2023 General $19,319 45
2022 General $29,223 44
2021 General $17,559 37
2020 General $346 16
2019 General $2,291 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Goentzel
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Brian Goentzel were reported at $6,656. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Brian Goentzel Pain Medicine median Middle half National median
2019 $2,291 $498 $126–$1,682 $163
2020 $346 $284 $80–$910 $114
2021 $17,559 $399 $112–$1,219 $132
2022 $29,223 $455 $137–$1,484 $149
2023 $19,319 $484 $128–$1,495 $160
2024 $23,120 $498 $131–$1,540 $164
2025 $6,656 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Relievant Medsystems, Inc. $59,746 85 payments
  2. Boston Scientific Corporation $28,236 53 payments
  3. Abbott Laboratories $7,426 86 payments
  4. Vertos Medical, Inc. $2,378 7 payments
  5. Spinal Simplicity, LLC $390 6 payments
  6. SPR Therapeutics, Inc $114 3 payments
  7. Vertiflex, Inc. $87 2 payments
  8. Stryker Corporation $82 1 payment
  9. Pfizer Inc. $41 3 payments
  10. Nevro Corp. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $65,900 36 payments
  2. Consulting Fee $18,668 13 payments
  3. Travel and Lodging $8,499 42 payments
  4. Food and Beverage $5,448 156 payments
Products named General payments · program years 2019–2025
  1. Intracept Pain $52,083 69 payments
  2. Intracept Pain $27,489 27 payments
  3. Intracept Pain $17,510 32 payments
  4. Intracept Pain $17,510 32 payments
  5. Intracept Pain $17,510 32 payments
  6. Intracept Pain $13,941 22 payments
  7. Intracept Pain $13,941 22 payments
  8. Intracept Contains (1)Intracept RF Probe (2)Intracept Access Instruments_NMOD $6,407 15 payments
  9. PROCLAIM $4,188 13 payments
  10. mild Device Kit $2,118 3 payments
  11. Other $5,287 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

116

Median for Pain Management: 951

Drug cost

$498

Median for Pain Management: $26,034

Branded share of claims

24.1%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 28 $167
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 28 $164
Cephalexin Generic 14 $96
Tramadol Hcl Generic 46 $72

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$194,306

Medicare's payments for the services billed

Medicare patients

523

Average age 74

Services billed

1,904

326 women, 197 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Diabetes 31%
Chronic kidney disease 28%
Depression 28%
Atrial fibrillation 21%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record